New treatments for acute myeloid leukemia: how much has changed?
- PMID: 33184492
- DOI: 10.1038/s41375-020-01084-2
New treatments for acute myeloid leukemia: how much has changed?
Comment on
-
Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing?Leukemia. 2021 Jun;35(6):1571-1585. doi: 10.1038/s41375-020-01058-4. Epub 2020 Oct 19. Leukemia. 2021. PMID: 33077867
References
-
- Martinez-Cuadrón D, Serrano L, Gil C, Tormo M, Martínez-Sánchez P, Pérez-Simón J, et al. Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing? Leukemia. e-published 19 October 2020
-
- Wei AH, DiNardo CD. How I treat acute myeloid leukemia in the era of new drugs. Blood. 2020;135:85–96. - DOI
-
- DiNardo CD, Jonas BA, Pullarkat V, Thirman MV, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617–29. - DOI
-
- Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, et al. Venetoclax + LDAC for newly-diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized, placebo-controlled trial. Blood. 2020;135:2137–45. - DOI
-
- Cortes JE, Heidel FH, Hellmann A, Fiedler W, Smith BD, Robak T, et al. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia. 2019;33:379–89. - DOI
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
